CLOSE

Specials

  • March
  • June
  • September
  • Bioanalytical Services
  • Life Science Analytics
  • Life Science Compliance
  • Bioanalytical Services APAC
  • APAC
  • Europe

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
APAC
  • Home
  • News
  • Contributors
  • Magazine
  • Conferences
  • Newsletter
  • About

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • Contributers

Recommended Insights

Managing Risk and Minimizing the...

Timothy Korwan, Director, New Product Development...

In Personalized Medicine Logistics,...

Scott Ohanesian, Senior VP Commercial Operations,...

Unlock the Power of Data

Jijo James, M.D., M.P.H., Chief Medical Officer,...

A Growing Reliance on Outsourcing Warrants...

Greg Aimi, Vice President, Team Manager, Supply...

AI Can Improve Patient Outcomes, but will...

Ryan Billings, MS, MBA, Executive Director, Digital...

Are Wearables and Sensors the Key to...

Marie McCarthy, Director, Product Innovation, ICON plc

What is Next After Serialisation?

Ulrike Kreysa, Senior Vice-President of Healthcare, GS1

The Challenge of Complex Biologics...

Ron Guido, VP, Regulatory Affairs, IRX Therapeutics

Managing Risk and Minimizing the...

Timothy Korwan, Director, New Product Development...

In Personalized Medicine Logistics,...

Scott Ohanesian, Senior VP Commercial Operations,...

Unlock the Power of Data

Jijo James, M.D., M.P.H., Chief Medical Officer,...

A Growing Reliance on Outsourcing Warrants...

Greg Aimi, Vice President, Team Manager, Supply...

AI Can Improve Patient Outcomes, but will...

Ryan Billings, MS, MBA, Executive Director, Digital...

Are Wearables and Sensors the Key to...

Marie McCarthy, Director, Product Innovation, ICON plc

What is Next After Serialisation?

Ulrike Kreysa, Senior Vice-President of Healthcare, GS1

The Challenge of Complex Biologics...

Ron Guido, VP, Regulatory Affairs, IRX Therapeutics

How Technology is Disrupting the Pharma and Life Sciences Industry

By Colin Boatwright, CIO, Ironshore Pharmaceuticals Inc
Tweet

The Pharma and Life Sciences have a reputation of lagging behind in certain technology areas, either because of fears around regulatory concerns or the cost of migrating legacy applications. Founded or not, companies with a legacy set of applications face a challenge of how to move to modern solutions like Cloud, robotic process automation, micro-services, AI/ML, AR/ VR, and the host of other acronyms you read about daily.


Add to those concerns, from a pure financial point of view, it rarely makes sense: retiring a fully capitalized system with very few resources supporting it cannot be justified in a vacuum. But the reality is that your legacy systems are the anchor that will keep you moving forward.


It’s more than the fact that newly hired employees may prefer to work on more modern applications. It’s more than the issue of silos working separately, and not overall outcomes based. Legacy applications will always be the long pole in the tent.


You can certainly put in an integration platform, but you will always find yourself throttled by the underlying legacy systems. So where do you start?


First, start with a vision … something akin to “We will be 100% cloud-based by 2023” and pivot your entire organization to that goal. Don’t create multiple separate initiatives with as many architects. Instead, create a cross-functional group that understands the vision and has the technical abilities to create.


This may mean pulling people out of their groups into a “Vision 2023” group. Focus them on how to power outcomes, getting your data ready for future technologies, and blueprinting thigs like AI/ML but delivering on the practical. Whiteboard your pain points and divide into two categories: “Simple” and “Complex.”


The simple should be simple; complex should be possible. Often, we make the simple complex and the complex impossible. For the “Simple” ones, just do them.


Don’t debate, don’t create committees, don’t let internal politics stop you.


If you cannot get past the simple, you’ll never get to the complex. For the “Complex” ones, break them down so they can be simple and put them out on a Horizon Chart: Horizon 1-3. Spend time on what Horizon 3 should look like, but agree to a clear vision on how to get to your end-state. Getting from “here” to “there” is never onestep, but a journey. It is, however, a journey needs that needs an endpoint.


As you make your journey to cloud-only, new initiatives should be cloud-first … don’t go and create “new legacy” applications simple because you don’t think your organization is ready. You can make it ready thru leadership. Use new initiatives as an opportunity for “mini disruptions.”


It’s not a technology issue but a cultural one. Your SOPs can survive the move to the Cloud, don’t think otherwise. The major cloud players have already figured it out better than you can … or at least, have some trust that they have. Pick one of the major players and let that be your architecture: don’t get lost in the “best in breed” mentality, pick the environment that works best for you. Mostly a Microsoft shop? Go Azure and move on. Same thought process with Google and AWS.


Finally, remember modernizing IT never stops. The legacy applications of today were the forward-thinking ones of yesterday. As you move away from your legacy applications, legacy data centers, legacy business process, legacy anything, remember that what you replace it with has the danger of becoming the next evil legacy application. So never forget to keep your applications regularly updated, exploring the next “new” thing and decide if you should advance your applications in that direction.


Small, iterative upgrades will keep you current and avoid the situation many are in today with systems that were left on auto pilot, but have nowhere left to go.


Weekly Brief

loading
Towards a New World Order
> <
  • Other 2021

    Top Vendors

    Current Issue
  • Other 2020

    Top Vendors

    Current Issue

Read Also

Maintaining A Patient-Focused Community Pharmacy With Consumer Technology

Dale Danilewitz, Executive Vice President & CIO, AmerisourceBergen [NYSE:ABC]
Maintaining A Patient-Focused Community Pharmacy With Consumer Technology

Navigating Technology Transformations for CIO Success

Steve Betts, CIO, Health Care Service Corporation
Navigating Technology Transformations for CIO Success

Enhancing Rural Medicine and Healthcare

Jake Dorst, Chief Information & Innovation Officer, Tahoe Forest Hospital District
Enhancing Rural Medicine and Healthcare

Efficient Data Management in the Healthcare Space

Jim Simpson, SVP & CIO, AvMed
Efficient Data Management in the Healthcare Space
Life Sciences: Macro View

Life Sciences: Macro View

Rajeev Nair, CIO, J. Knipper & Company
The Next Big Thing in Pharma and Life sciences industry

The Next Big Thing in Pharma and Life sciences industry

Mark Williams, VP CIO, ACI Clinical

The Changing Role of CIO in the Biopharmaceutical Industry

Andy Newsom, CIO, CSL Behring
The Changing Role of CIO in the Biopharmaceutical Industry

XR in Healthcare: Simple Evolution or Amazing Revolution?

Grégory Maubon, Digital Coordinator CIO/CDO, HCS Pharma
XR in Healthcare: Simple Evolution or Amazing Revolution?
Loading...

Copyright © 2021 Life Science Review . All rights reserved. |  Subscribe follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/cioviewpoint/how-technology-is-disrupting-the-pharma-and-life-sciences-industry-nwid-25.html